Growth during treatment of familial hypercholesterolemia

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Growth during treatment of familial hypercholesterolemia. / Hansen, Dorthe; Michaelsen, Kim Fleischer; Skovby, Flemming.

I: Acta Pædiatrica, Bind 81, Nr. 12, 1992, s. 1023-1025.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hansen, D, Michaelsen, KF & Skovby, F 1992, 'Growth during treatment of familial hypercholesterolemia', Acta Pædiatrica, bind 81, nr. 12, s. 1023-1025. https://doi.org/10.1111/j.1651-2227.1992.tb12167.x

APA

Hansen, D., Michaelsen, K. F., & Skovby, F. (1992). Growth during treatment of familial hypercholesterolemia. Acta Pædiatrica, 81(12), 1023-1025. https://doi.org/10.1111/j.1651-2227.1992.tb12167.x

Vancouver

Hansen D, Michaelsen KF, Skovby F. Growth during treatment of familial hypercholesterolemia. Acta Pædiatrica. 1992;81(12):1023-1025. https://doi.org/10.1111/j.1651-2227.1992.tb12167.x

Author

Hansen, Dorthe ; Michaelsen, Kim Fleischer ; Skovby, Flemming. / Growth during treatment of familial hypercholesterolemia. I: Acta Pædiatrica. 1992 ; Bind 81, Nr. 12. s. 1023-1025.

Bibtex

@article{c90186435a3e4c55a8c7bf7f03d40216,
title = "Growth during treatment of familial hypercholesterolemia",
abstract = "Treatment of hypercholesterolemic children with restriction of dietary saturated fat may result in an inadequate supply of energy for normal somatic growth. We examined the growth of 30 children with familial hypercholesterolemia, some of whom were also treated with colestipol, a bile acid‐binding resin. The median duration of treatment was 8.5 years in 13 patients on diet only, and 5.5 years + 3.5 years in 17 patients treated with diet followed by diet and colestipol. Statistically significant reductions in serum total cholesterol were obtained in both groups. The SD scores for both height/age and weight/age decreased by approximately 0.4 during dietary treatment (p<0.05), but were not affected by treatment with colestipol. These results document the risk of growth retardation during dietary treatment of children with familial hypercholesterolemia.",
keywords = "Cholesterol, Colestipol, Diet, Familial hypercholesterolemia, Growth",
author = "Dorthe Hansen and Michaelsen, {Kim Fleischer} and Flemming Skovby",
year = "1992",
doi = "10.1111/j.1651-2227.1992.tb12167.x",
language = "English",
volume = "81",
pages = "1023--1025",
journal = "Acta Paediatrica",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "12",

}

RIS

TY - JOUR

T1 - Growth during treatment of familial hypercholesterolemia

AU - Hansen, Dorthe

AU - Michaelsen, Kim Fleischer

AU - Skovby, Flemming

PY - 1992

Y1 - 1992

N2 - Treatment of hypercholesterolemic children with restriction of dietary saturated fat may result in an inadequate supply of energy for normal somatic growth. We examined the growth of 30 children with familial hypercholesterolemia, some of whom were also treated with colestipol, a bile acid‐binding resin. The median duration of treatment was 8.5 years in 13 patients on diet only, and 5.5 years + 3.5 years in 17 patients treated with diet followed by diet and colestipol. Statistically significant reductions in serum total cholesterol were obtained in both groups. The SD scores for both height/age and weight/age decreased by approximately 0.4 during dietary treatment (p<0.05), but were not affected by treatment with colestipol. These results document the risk of growth retardation during dietary treatment of children with familial hypercholesterolemia.

AB - Treatment of hypercholesterolemic children with restriction of dietary saturated fat may result in an inadequate supply of energy for normal somatic growth. We examined the growth of 30 children with familial hypercholesterolemia, some of whom were also treated with colestipol, a bile acid‐binding resin. The median duration of treatment was 8.5 years in 13 patients on diet only, and 5.5 years + 3.5 years in 17 patients treated with diet followed by diet and colestipol. Statistically significant reductions in serum total cholesterol were obtained in both groups. The SD scores for both height/age and weight/age decreased by approximately 0.4 during dietary treatment (p<0.05), but were not affected by treatment with colestipol. These results document the risk of growth retardation during dietary treatment of children with familial hypercholesterolemia.

KW - Cholesterol

KW - Colestipol

KW - Diet

KW - Familial hypercholesterolemia

KW - Growth

UR - http://www.scopus.com/inward/record.url?scp=0027082668&partnerID=8YFLogxK

U2 - 10.1111/j.1651-2227.1992.tb12167.x

DO - 10.1111/j.1651-2227.1992.tb12167.x

M3 - Journal article

C2 - 1290846

AN - SCOPUS:0027082668

VL - 81

SP - 1023

EP - 1025

JO - Acta Paediatrica

JF - Acta Paediatrica

SN - 0803-5253

IS - 12

ER -

ID: 258034733